Spain's Almirall warns of delay in approval for psoriasis drug

(Reuters) - Spanish pharma company Almirall said on Tuesday it expects the launch of psoriasis treatment drug, Tildrakizumab, in Europe to get delayed by at least six months due to regulatory hurdles.

from Reuters: Health News http://reut.rs/2hqiXv1